Pain News and Research

Latest Pain News and Research

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

12 Jun 2014

8.5 million on Medicare get opioids

The number of senior citizens getting narcotic painkillers and anti-anxiety medications under Medicare's prescription drug program is climbing sharply, and those older patients are being put on the drugs for longer periods of time, a USA TODAY examination of federal data shows.

12 Jun 2014

Study identifies correlation between miRNAs and osteoarthritis

The results of a study presented today at the European League Against Rheumatism Annual Congress identify a correlation between the presence of biomarkers in the blood, known as micro RNAs (miRNAs), and the development of severe osteoarthritis (OA) of the knee or hip joint. The findings suggest that miRNAs may be used as biomarkers to predict severe OA disease in individuals.

12 Jun 2014

Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel).

11 Jun 2014

New research collaboration aims to develop better therapies for autoimmune diseases

Seattle Children's Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.

11 Jun 2014

Hunterdon Regional Cancer Center offers immuno-therapy clinical trial for lung cancer

According to the American Cancer Society, lung cancer is the second most common cancer among men and women and the leading cause of death in the United States. In 2014, it is estimated that 224,210 people will be diagnosed with lung cancer.

11 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

First Edition: June 11, 2014

Today's headlines include a range of stories about the upset of House Majority Leader Eric Cantor -- a Virginia primary election shocker -- as well as continuing coverage of health law implementation issues and congressional responses to the VA's health care troubles.

11 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

1% of adults experience headaches associated with sexual activity, shows report

About 1 percent of adults report they have experienced headaches associated with sexual activity, and that such headaches can be severe.

10 Jun 2014

InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

InSite Vision Incorporated and Senju Pharmaceutical Co., Ltd. today announced that they have entered into a collaboration and license agreement to develop and market InSite's azithromycin ophthalmic solution using DuraSite® including AzaSite® 1% and AzaSite XtraTM 2% ocular antibiotics in Japan. Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales.

10 Jun 2014

New innovative body suit improves horse riders’ balance, symmetry, poor posture

HORSE riders' balance, symmetry and poor posture could be improved thanks to an innovative body suit that works with motion sensors, commonly used by movie makers and the video games industry.

10 Jun 2014

Combined MMRV vaccine slightly increases risk of febrile seizures in children

The combined measles-mumps-rubella-varicella (MMRV) vaccine shows a slightly increased risk of febrile seizures in children, compared with the previously separate vaccines for MMR and varicella (chickenpox) (MMR+V), according to an article in CMAJ (Canadian Medical Association Journal).

10 Jun 2014

Function restoration benefits for fibromyalgia in musculoskeletal disorders

Functional restoration programmes may help to suppress fibromyalgia in some patients with chronic disabling occupational musculoskeletal disorders, but more may need to be done to overcome longer-term related disability, research suggests.

9 Jun 2014

Lifestyle changes, natural supplements can help women fight weight gain during menopause

Menopause, which tends to occur in midlife, is often known for causing weight gain. Menopausal weight gain is frequently caused by the hormonal changes that occur as the ovaries slow their production of estrogen and progesterone.

9 Jun 2014

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval.

9 Jun 2014

Virtual reality can be effective adjunct for chronic and acute pain conditions

Chronic pain due to disease or injury is common, and even prescription pain medications cannot provide acceptable pain relief for many individuals.

9 Jun 2014

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.

9 Jun 2014

Kush Creams to manufacture and distribute medical marijuana product, 5 Hour High

Alternaturals, Inc., Symbol (OTCPink:ANAS) today announced that it has chosen Kush Creams, a Washington based, medical marijuana grower and distributor with award winning strains and products, to manufacture and distribute its long awaited medical marijuana product, 5 Hour High©.

9 Jun 2014